Theravance Biopharma Inc (TBPH)

Theravance Biopharma, Inc.'s stock has been impacted by several events in the past six months. The company is scheduled to report its third-quarter 2025 financial results on November 10, 2025. B. Riley initiated coverage of Theravance Biopharma with a "Buy" rating in September 2025. Enrollment was completed in the pivotal Phase 3 CYPRESS study of Ampreloxetine for symptomatic neurogenic orthostatic hypotension due to Multiple System Atrophy in August 2025. Also in August 2025, Theravance Biopharma and Mylan settled with Cipla regarding Yupelri inhalation solution. The company reported its second-quarter 2025 financial results on August 12, 2025, with Yupelri net sales increasing 22% year-over-year. Earlier, in May 2025, Theravance Biopharma reported Q1 EPS of (27c) and revenue of $15.4M. In February 2025, the company reported Q4 EPS of (31c) and revenue of $18.75M, highlighting record fourth-quarter Yupelri net sales and profitability.

Demand for Theravance Biopharma's products can be influenced by seasonality, particularly for its COPD treatment, Yupelri. Exacerbations of chronic obstructive pulmonary disease (COPD) exhibit a distinct seasonal pattern, with higher rates observed during the coldest months of the year, typically January, February, and March, in the northern hemisphere. For neurogenic orthostatic hypotension (nOH), symptoms can be more pronounced in warmer months due to factors such as heat and humidity.

Theravance Biopharma, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines, primarily in respiratory diseases, inflammatory and immunology, and rare disorders. The company's flagship product, Yupelri, is approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company's pipeline also includes investigational drugs for gastrointestinal and inflammatory diseases, and ampreloxetine, in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). Theravance Biopharma generates revenue through product sales, licensing agreements, and strategic collaborations.

Theravance Biopharma, Inc. operates through U.S. and Europe geographical segments. Its headquarters are located in George Town, Cayman Islands, and the company also maintains corporate offices in Dublin, Ireland, and research facilities in the Bay Area of California.

Theravance Biopharma has actively worked to enhance its brand reputation through disease education. In October 2025, the company launched the "Power in the Periphery" disease education campaign aimed at healthcare professionals to raise awareness and deepen scientific understanding of neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA). No significant negative events impacting the company's reputation were identified in the past year.

Public Companies and Individual Investors collectively hold the largest share at 73.98%. Mutual Funds account for 9.53% of the ownership, while Insiders hold 2.26%. Other Institutional Investors make up 0.19% of the ownership.